30 Apr 2014

Decision in the cases of Paco Climent Gregori and Philipp Aleksanyan


ITF Anti-Doping

30 April 2014 – London, ENGLAND - The International Tennis Federation announced today that Paco Climent Gregori and Philipp Aleksanyan have been found to have committed Anti-Doping Rule Violations under Article 2.1 of the Tennis Anti-Doping Programme (presence of a Prohibited Substance in a Player’s Sample).

Mr Climent Gregori, a 16 year-old player from Spain, and Mr Aleksanyan, an 18 year-old player from Russia, provided urine samples on 8 September in association with their participation in the F30 Futures Event in Madrid, Spain. Those samples were sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and were found to contain stanozolol, which is a Prohibited Substance under section S1 (Anabolic agents) of the 2013 WADA List of Prohibited Substances and Prohibited Methods, and is therefore also prohibited under the Tennis Anti-Doping Programme (the “Programme”). Mr Climent Gregori and Mr Aleksanyan were each therefore charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme.

Both players asserted that the stanozolol, for which they did not hold a valid TUE, had entered their system through their ingestion of pills provided to them by an unidentified pharmacist whom they befriended at the Granadia Tennis Club. This assertion did not meet the preconditions of Article 10.5 of the Programme (no fault or negligence, or no significant fault or negligence). The players’ attempt to rely on Article 10.5.4 of the Programme (voluntary admission) was also rejected.

Mr Climent Gregori’s and Mr Aleksanyan’s commissions of Anti-Doping Rule Violations under Article 2.1 of the Programme were confirmed, and it was determined that they are suspended from participation for a period of two years, commencing from 5 November 2013, the date on which they were provisionally suspended, and so ending at midnight on 4 November 2015. It was also determined that both players’ results at the F30 Futures event and all subsequent events in which they competed up to 4 November 2013 should be disqualified, with resulting forfeiture of the ranking points and prize money that they won at those events.

The Tennis Anti-Doping Programme is a comprehensive and internationally recognised drug-testing programme that applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP, and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed in accordance with the requirements of the Tennis Anti-Doping Programme and World Anti-Doping Code. More background information on the Programme, sanctions, tennis statistics and related information can be found at www.itftennis.com/antidoping.